A Double Blind Clinical Trial of DCS for Food Anxiety
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication)
augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa. The
investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be
reduced more in the DCS relative to placebo condition (c) participants in the DCS condition
will have a greater increase in Body Mass Index.